Print

Lay Description

This is a non-randomized biomarker study with the aim to evaluate the relationship between APOBEC3B (A3B) expression in primary head and neck cancers (HNC), anus, and cervix tumors and pathologic response to definitive chemoradiation therapy.

Category

  • Cancers and Other Neoplasms
IRB Number
STUDY00000230
NCT Number
NCT # not yet entered

Eligibility

Eligible Ages
18
Eligible Genders
all
Accepts Healthy Volunteers

Inclusion Criteria

• Patients must be at least 18 years of age.

• Patients must have a suspicion for head and neck cancer needing to undergo biopsy for diagnosis and ultimately definitive-intent chemoradiation

• Patients must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

Other Exclusion Criteria:

• Patients with distant metastatic disease as determined by the treating provider.

• Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient’s safety or study endpoints/validity.

Study Design

Arm Groups

Study Contact

Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu

Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu

Kathleen Rodriguez
210-450-1365
rodriguezk3@uthscsa.edu

Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu

Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu

Principal Investigator
Shraddha Dalwadi